FDA
-
-
-
-
-
-
-
Acromegaly Market Poised for Significant Expansion During the Forecast Period (2026-2036) as New Treatment Options Emerge | DelveInsight
-
-
-
-
-
-
-
Ascendis Pharma's (ASND) PDUFA Extension a Minor Issue - Cantor Fitzgerald
-
-
-
-
-
-
-
Ascendis Pharma Reports Third Quarter 2025 Financial Results
-
-
-
-
-
-
-
Dr. Jethro Ekuta Joins BP Logix Life Sciences Strategic Advisory Board
-
-
-
-
-
-
-
Ascendis Pharma (ASND) Submits U.S. NDA for TransCon CNP for the Treatment of Children with Achondroplasia
-
-
-
-
-
-
-
YORVIPATH® (Palopegteriparatide) Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in Adults
-
-
-
-
-
-
-
Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

